Azacitidine and Venetoclax in Previously Untreated Acute ... | 合法藥品大搜索
由CDDiNardo著作·2020·被引用606次—Background:Olderpatientswithacutemyeloidleukemia(AML)haveadismalprognosis,evenaftertreatmentwithahypomethylatingagent.
由 CD DiNardo 著作 · 2020 · 被引用 606 次 — Background: Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent.
Azacitidine and venetoclax in previously untreated acute myeloid leukemia Venetoclax arac AML Venetoclax voriconazole Azacitidine AML Decitabine venetoclax AML protocol Gilteritinib or chemotherapy for relapsed or refractory FLT3 mutated AML Low-dose ara c and venetoclax protocol VIALE-C Azacitidine AML Venetoclax AML viale-c Venetoclax-posaconazole Pubmed azacitidine and venetoclax in previously untreated acute myeloid leukemia Cc486 nejm MDS azacitidine venetoclax Genomic classification and prognosis in acute myeloid leukemia Venetoclax voriconazole interaction Venclexta posaconazole How we use venetoclax with hypomethylating agents Venetoclax dose Venetoclax AML dose Venetoclax renal dose adjustment venetoclax antifungal prophylaxis TOWELL 副作用 歐西 拉 因 bupronil副作用 "先靈 " 氫化皮質酮副作用 羅根演員名單 頭孢子素副作用 泛艾黴素 pharmorubicin小紅莓
Azacitidine and Venetoclax in Previously Untreated Acute ... | 合法藥品大搜索
由 CD DiNardo 著作 · 2020 · 被引用 606 次 — Background: Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Read More
Cost | 合法藥品大搜索
由 KK Patel 著作 · 2021 · 被引用 7 次 — The phase 3 VIALE-A trial reported that venetoclax in combination with ... patients with previously untreated acute myeloid leukemia (AML). Read More
Venetoclax combined with decitabine or azacitidine ... | 合法藥品大搜索
由 CD DiNardo 著作 · 2019 · 被引用 998 次 — Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. Read More
Venetoclax plus azacitidine in Japanese patients with ... | 合法藥品大搜索
由 K Yamamoto 著作 · 2022 — Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Read More
Safety and preliminary efficacy of venetoclax with decitabine ... | 合法藥品大搜索
由 CD DiNardo 著作 · 2018 · 被引用 463 次 — Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non- ... Read More
Venetoclax and azacitidine compared with induction ... | 合法藥品大搜索
由 EM Cherry 著作 · 2021 · 被引用 1 次 — Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not ... Read More
[Short | 合法藥品大搜索
2022年4月6日 — ... with azacitidine (Ven+AZA) in previously untreated patients unfit ... venetoclax combined with azacitidine in acute myeloid leukemia: a ... Read More
Venetoclax Combined With Low | 合法藥品大搜索
由 AH Wei 著作 · 2019 · 被引用 399 次 — Venetoclax plus LDAC has a manageable safety profile, ... Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results ... Read More
Resistance to venetoclax and hypomethylating agents in ... | 合法藥品大搜索
由 AN Saliba 著作 · 2021 · 被引用 11 次 — ... hypomethylating agents (HMA) decitabine or azacitidine in inducing remission in older, previously untreated patients with acute myeloid leukemia (AML), ... Read More
相關資訊整理
【唯可來膜衣錠 10毫克】1. 慢性淋巴球性白血病 (CLL):與obinutuzumab併用,適用於先前未曾接受過治療的慢性淋巴球性白血病病人。適用於治療先前曾接受至少一線治療之具有或不具有17p缺失的慢性淋巴球性白血病病人。2. 急性骨髓性白血病 (AML):併用低甲基化劑 (hypomethylating agent) 或併用低劑量cytarabine適用於無法接受高強度化學治療之初診斷急性骨髓性白血病 (AML) 病人。
藥品名稱:唯可來膜衣錠10毫克許可證字號:衛部藥輸字第027357號許可證種類:製 劑適應症:1.慢性淋巴球性白血病(CLL):與obinu...
【委丹扎注射劑】治療骨髓增生不良症候群高危險性的病患High Risk MDS:頑固性貧血併有過量芽細胞 (RA with excess blasts, RAEB)、轉變中的頑固性貧血併有過量芽細胞 (RAEB in transformation, RAEB-T)、及慢性骨髓單核細胞性白血病 (chronic myelomonocytic leukemia, CMMoL)
藥品名稱:委丹扎注射劑許可證字號:衛署藥輸字第025154號許可證種類:製 劑適應症:治療骨髓增生不良症候群高危險性的病患High...
【"德國"委丹扎注射劑】治療骨髓增生不良症候群高危險性的病患High Risk MDS:頑固性貧血併有過量芽細胞(RA with excess blasts,RAEB)、轉變中的頑固性貧血併有過量芽細胞(RAEB in transformation,RAEB-T)、及慢性骨髓單核細胞性白血病(chronic myelomonocytic leukemia, CMMoL)。Vidaza適用於治療65歲(含)以上、不適合接受HSCT或密集化學治療、且骨髓芽細胞比例>30%的AML成人患者(依據WHO分類)。
藥品名稱:"德國"委丹扎注射劑許可證字號:衛署藥輸字第025781號許可證種類:製 劑適應症:治療骨髓增生不良症候群高危險性的病...
【唯可來膜衣錠 100毫克】1. 慢性淋巴球性白血病 (CLL):與obinutuzumab併用,適用於先前未曾接受過治療的慢性淋巴球性白血病病人。適用於治療先前曾接受至少一線治療之具有或不具有17p缺失的慢性淋巴球性白血病病人。2. 急性骨髓性白血病 (AML):併用低甲基化劑 (hypomethylating agent) 或併用低劑量cytarabine適用於無法接受高強度化學治療之初診斷急性骨髓性白血病 (AML) 病人。
藥品名稱:唯可來膜衣錠100毫克許可證字號:衛部藥輸字第027359號許可證種類:製 劑適應症:1.慢性淋巴球性白血病(CLL):與obin...
【療德妥軟膠囊25毫克】於新確診為FLT3突變陽性的急性骨髓性白血病(AML)成人病患之標準前導(daunorubicin併用cytarabine)與鞏固性化療(高劑量cytarabine)時合併使用Rydapt。
藥品名稱:療德妥軟膠囊25毫克許可證字號:衛部藥輸字第027426號許可證種類:製 劑適應症:於新確診為FLT3突變陽性的急性骨髓性...
【唯可來膜衣錠 50毫克】1. 慢性淋巴球性白血病 (CLL):與obinutuzumab併用,適用於先前未曾接受過治療的慢性淋巴球性白血病病人。適用於治療先前曾接受至少一線治療之具有或不具有17p缺失的慢性淋巴球性白血病病人。2. 急性骨髓性白血病 (AML):併用低甲基化劑 (hypomethylating agent) 或併用低劑量cytarabine適用於無法接受高強度化學治療之初診斷急性骨髓性白血病 (AML) 病人。
藥品名稱:唯可來膜衣錠50毫克許可證字號:衛部藥輸字第027358號許可證種類:製 劑適應症:1.慢性淋巴球性白血病(CLL):與obinu...